Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications

Adv Ther. 2023:1–17 doi: 10.1007/s12325-023-02445-w Epub ahead of print

Analysis of pooled data from the baricitinib clinical development programmes finds a low incidence rate of MACE, myocardial infarction, lung cancer, VTE, and overall mortality in patients <65 years without risk factors.

JAK inhibitors have been linked to a possible class effect associated with particular adverse events, such as MACE, VTE, and malignancy. As such, further characterisation of adverse events of special interest (AESIs) in at-risk populations will improve the risk-benefit assessment for individual patients and diseases. To help address this, Taylor, et al. expand on the safety of baricitinib for AESI, across all approved indications.